Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.53 |
| ▸ | PPARD | Q03181 | 12/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483429 | 0.88 | PPARA (0.45) | PPARAPPARDPPARGKCNH2SRC | |
| SCHEMBL23158257 | 0.85 | PPARA (0.52) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL20702486 | 0.83 | SRC (0.46) | PPARAPPARDPPARGKCNH2SRC | |
| SCHEMBL11893197 | 0.82 | SRC (0.45) | PPARAPPARDPPARGKCNH2SRC | |
| SCHEMBL14988854 | 0.82 | PPARA (0.55) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL5472572 | 0.81 | PPARA (0.40) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL814693 | 0.81 | FBP1 (0.49) | PPARAPPARDPPARGSRC | |
| SCHEMBL6362308 | 0.79 | FBP1 (0.47) | PPARAPPARDPPARG | |
| SCHEMBL14290098 | 0.76 | SRC (0.43) | PPARAPPARDPPARGKCNH2SRC | |
| SCHEMBL21753046 | 0.76 | SRC (0.40) | PPARAPPARDPPARGKCNH2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11465967-B2 | Process for the preparation of elafibranor and novel synthesis intermediates | ADVITECH ADVISORY AND TECHNOLOGIES SA (CH) | 2022-10-11 | — | — | US | disclosed |
| US-20210101866-A1 | PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATES | ADVITECH ADVISORY AND TECHNOLOGIES SA (CH) | 2021-04-08 | — | — | US | disclosed |
| EP-3661914-A1 | PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATES | Advitech Advisory and Technologies SA (CH) | 2020-06-10 | — | — | EP | disclosed |
| CN-111183132-A | Preparation method of Elafibranor and novel synthetic intermediate | 阿德万泰克咨询与技术股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2020079541-A1 | PROCESS FOR PREPARATION OF ELAFIBRANOR | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK LIFE SCIENCES LIMITED (IN) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019025017-A1 | PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATES | ADVITECH ADVISORY AND TECHNOLOGIES SA (CH) | 2019-02-07 | — | — | WO | disclosed |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-09-06 | — | — | US | disclosed |
| EP-1731513-A1 | PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101866-A1 | PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATES | FDPS, CYP4F11, CYP4F3 | PPARA 1176/4885PPARD 1147/4885PPARG 1047/4885 |
| US-11465967-B2 | Process for the preparation of elafibranor and novel synthesis intermediates | FDPS, CYP4F11, CYP4F3 | PPARA 1176/4885PPARD 1147/4885PPARG 1047/4885 |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | PPARA, PPARG, PPARD | PPARA 1/4885PPARD 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.